SCHEMBL30737861

SCHEMBL30737861

COc1cc(OC)cc(-c2cc3cnc(NCCCO)nc3nc2NC(=O)NC(C)(C)C)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 20/20 1.00
▸ FGFR2 P21802 12/20 1.00
▸ FGFR4 P22455 12/20 1.00
▸ FGFR3 P22607 12/20 1.00
▸ KDR P35968 12/20 1.00
▸ FLT1 P17948 9/20 1.00
▸ FLT4 P35916 9/20 1.00
▸ SRC P12931 2/20 0.79
▸ GLA P06280 1/20 0.79
▸ CSK P41240 1/20 0.79
▸ KMT2A Q03164 1/20 0.79
▸ ATM Q13315 1/20 0.79
▸ EGFR P00533 1/20 0.68
▸ PDGFRB P09619 2/20 0.59
▸ PDGFRA P16234 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2470675 0.92 FGFR1 (0.85) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL5619204 0.91 FGFR1 (0.84) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL22144559 0.91 FGFR1 (0.95) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL22532273 0.91 FGFR1 (0.82) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL15047128 0.90 FGFR1 (0.81) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL19848922 0.89 FGFR1 (0.80) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL15047127 0.89 FGFR1 (0.80) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL24490071 0.88 FGFR1 (0.79) FGFR1FGFR2FGFR4FGFR3KDR
Pd-173074 SCHEMBL29828472 0.88 FGFR1 (1.00) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL29390591 0.88 FGFR1 (0.79) FGFR1FGFR2FGFR4FGFR3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023240271-A1 USE OF VEGFR2 AND FGFR1 INHIBITORS IN THERAPY FOUNTAIN THERAPEUTICS INC. (US) 2023-12-14 — — WO claimed
WO-2023240271-A1 USE OF VEGFR2 AND FGFR1 INHIBITORS IN THERAPY FOUNTAIN THERAPEUTICS INC. (US) 2023-12-14 — — WO disclosed
Send feedback